Manchester Capital Management’s AstraZeneca AZN Stock Holding History

Manchester Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$268K	Hold	1,415	–	–	0.03%	239
2026 Q1	$279K	Buy	1,415 +57	+4%	+$11K	0.04%	231
2025 Q4	$250K	Buy	1,358 +1,312	+2,852%	+$230K	0.03%	246
2025 Q3	$7.06K	Buy	+46	New	+$6.96K	﹤0.01%	912
2021 Q3	–	Sell	-71	Closed	-$8K	–	1032
2021 Q2	$8K	Buy	+71	New	+$7.79K	﹤0.01%	512
2015 Q1	–	Sell	-1,731	Closed	-$122K	–	568
2014 Q4	$122K	Sell	1,731 -903	-34%	-$64.7K	0.02%	493
2014 Q3	$188K	Buy	2,634 +935	+55%	+$68.4K	0.03%	359
2014 Q2	$126K	Buy	+1,699	New	+$123K	0.02%	506

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Manchester Capital Management's AZN Position: Q2 2026 in Review

Manchester Capital Management held its AstraZeneca (AZN) position steady in Q2 2026 at 1,415 shares worth $268K. The position accounts for 0.03% of the portfolio, ranked #239.

Manchester Capital Management first reported a position in AZN in Q2 2014 and has held it in 8 quarters since. The position peaked at $279K in Q1 2026. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Manchester Capital Management held 1,415 shares of AstraZeneca worth $268K as of Q2 2026.
Manchester Capital Management left its AstraZeneca share count unchanged in Q2 2026.
AstraZeneca made up 0.03% of Manchester Capital Management's portfolio in Q2 2026, its #239 holding.
Manchester Capital Management first reported a position in AstraZeneca in Q2 2014 and has held it in 8 quarters since.
Manchester Capital Management's AstraZeneca position peaked at $279K in Q1 2026.
1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Manchester Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.